CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Metabolites dosageother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04821336
NCT04821336N/ACompleted
CompareCT.gov

Cholesterol Metabolites (Dendrogenin A or DDA, 6-oxo-cholestane-3β,5α-diol or OCDO,...) Quantification in Malignant Versus Normal Human Thyroid Tissue Refractory to Iodine

Institut Claudius Regaud·observational·Posted Mar 29, 2021·Updated May 1, 2023

In Brief

An observational study evaluating Metabolites dosage for Thyroid Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer
CountriesFrance
CollaboratorsCancer Research Center of Toulouse

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMar 29, 2021
Enrollment StartApr 15, 2021
Primary CompletionSep 30, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.3 years ago

Interventions

Metabolites dosageother

On samples investigators will quantify cholesterol metabolite and dendrogenin A (DDA) and 6-oxo-cholestane-3β,5α-diol (ou OCDO) metabolites in malignant tissue sample on one hand, and in sane samples on other hand. The investigators will compare the rate of deregulation between sane and malignant ones.